Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 25;47(1):16.
doi: 10.1186/s13052-021-00962-4.

Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease

Alessandra Marchesi  1 , Donato Rigante  2   3 , Rolando Cimaz  4   5 , Angelo Ravelli  6 , Isabella Tarissi de Jacobis  1 , Alessandro Rimini  7 , Fabio Cardinale  8 , Marco Cattalini  9 , Andrea De Zorzi  1 , Rosa Maria Dellepiane  10 , Patrizia Salice  11 , Aurelio Secinaro  1 , Andrea Taddio  12   13 , Paolo Palma  1 , Maya El Hachem  1 , Elisabetta Cortis  14 , Maria Cristina Maggio  15 , Giovanni Corsello  15 , Alberto Villani  1
Affiliations
Review

Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease

Alessandra Marchesi et al. Ital J Pediatr. .

Abstract

Aim of these revised recommendations for the general management of Kawasaki disease is to encourage its prompter recognition and warrant the most appropriate therapy, based on ascertained scientific data, raising awareness of the complications related to misdiagnosis or delayed treatment. A set of 20 synthetic operative statements is herein provided, including the definition of Kawasaki disease, its protean presentations, clinical course and seminal treatment modalities of all disease phases. The application of these recommendations should improve prognosis of Kawasaki disease and prevent the progression to permanent vascular abnormalities, thereby diminishing morbidity and mortality.

Keywords: Aspirin; Children; Coronary artery abnormalities; Intravenous immunoglobulin; Kawasaki disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
General Treatment of patients with KD
Fig. 2
Fig. 2
Treatment of High-Risk patients with KD. (children less than 12 months or children having C-reactive protein higher than 200 mg/l, severe anemia at disease onset, albumin level below 2.5 g/dl, liver disease, overt coronary artery aneurysms, macrophage activation syndrome or septic shock)
See this image and copyright information in PMC

References

    1. Marchesi A, Tarissi De Jacobis I, Rigante D, Rimini A, Malorni W, Corsello G, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital J Pediatr. 2018;44:102. doi: 10.1186/s13052-018-0536-3. - DOI - PMC - PubMed
    1. Marchesi A, Tarissi De Jacobis I, Rigante D, Rimini A, Malorni W, Corsello G, et al. Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. Ital J Pediatr. 2018;44:103. doi: 10.1186/s13052-018-0529-2. - DOI - PMC - PubMed
    1. Kawasaki T. Acute febrile mucocutaneus syndrome with lymphoid involvement with specific desquamation of the finger and toes in children. Arerugi. 1967;16:178–222. - PubMed
    1. Yim D, Curtis N, Cheung M, Burgner D. Update on Kawasaki disease: epidemiology, aetiology and pathogenesis. J Paediatr Child Health. 2013;49:704–708. doi: 10.1111/jpc.12172. - DOI - PubMed
    1. Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. Front Pediatr. 2018;6:374. doi: 10.3389/fped.2018.00374. - DOI - PMC - PubMed

Substances